Hepatocellular Carcinoma Drugs Market Report 2025

The hepatocellular carcinoma drugs market size has grown strongly in recent years. It will grow from $1.16 billion in 2024 to $1.27 billion in 2025 at a compound annual growth rate (CAGR) of 9.1%. The growth in the historic period can be attributed to increased disease incidence, advancements in cancer research, global healthcare infrastructure improvement, regulatory approvals, awareness and early diagnosis initiatives.

The hepatocellular carcinoma drugs market size is expected to see strong growth in the next few years. It will grow to $1.77 billion in 2029 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to targeted therapies advancements, increasing geriatric population, healthcare personalization trends, global expansion of treatment access. Major trends in the forecast period include access to innovative therapies, patient-centric care, regulatory advancements, drug resistance mitigation strategies, collaborative research initiatives.

The hepatocellular carcinoma drug market is expected to witness substantial growth in the coming years due to the increasing incidence of hepatocellular carcinoma (HCC), the most common form of liver cancer. HCC originates in hepatocyte cells, the main type of liver cells, and is often associated with hepatitis B or C infections and cirrhosis. The rising occurrence of HCC is driving the demand for effective drugs to treat the disease. According to a 2023 report by the American Cancer Society, the estimated new cases of liver cancer in females in the United States increased from 12,660 in 2022 to 13,230 in 2023, highlighting the need for advancements in hepatocellular carcinoma drugs.

The growth of the hepatocellular carcinoma drugs market is further propelled by the increasing prevalence of hepatitis, an inflammatory condition of the liver linked to chronic hepatitis B (HBV) and hepatitis C (HCV) infections. Chronic hepatitis infections often lead to liver cirrhosis, a precursor to HCC, emphasizing the importance of drugs addressing hepatocellular carcinoma. As of April 2022, the European Centre for Disease Prevention and Control reported a notable number of hepatitis cases in various countries, including the UK, the US, Israel, and Japan. This escalating prevalence of hepatitis is a significant factor driving the growth of the hepatocellular carcinoma drugs market.

Major companies in the market are focusing on developing laboratory-produced molecules, particularly monoclonal antibodies (mAb). Monoclonal antibodies are engineered to mimic the immune system's ability to combat pathogens. AstraZeneca's FDA approval for Imjudo (tremelimumab) in combination with Imfinzi (durvalumab) for hepatocellular carcinoma treatment is a notable example of such developments. Imfinzi, a human monoclonal antibody targeting PD-L1, and Imjudo, targeting CTLA-4, work synergistically to enhance the immune response against cancer cells.

Leading companies in the hepatocellular carcinoma drugs market are actively creating innovative products, including liver cancer medications, to cater to larger customer bases, boost sales, and enhance overall revenue. Drugs for liver cancer encompass a diverse range of pharmaceutical interventions aimed at treating and managing the disease. As an example, in October 2022, Eli Lilly and Company, a pharmaceutical firm based in the United States, announced the approval of Cyramza (ramucirumab) by the National Medical Products Administration (NMPA) for the treatment of hepatocellular carcinoma in China. Cyramza is the first novel medicine to receive approval following a specific evaluation in a biomarker-enriched population of hepatocellular carcinoma (HCC) patients with alpha-fetoprotein (AFP) levels exceeding 400 ng/ml. The study results in Chinese patients demonstrated a consistent efficacy and safety profile comparable to the global population. This approval is expected to positively impact the clinical approach to liver cancer in China by introducing a new and effective treatment option for advanced HCC among Chinese patients.

In August 2023, Novartis AG, a pharmaceutical company based in Switzerland, completed the acquisition of Chinook Therapeutics Inc. for a deal valued at $3.2 billion. Through this strategic acquisition, Novartis aims to leverage the combined resources and expertise to advance the development of promising treatments for individuals with rare and severe chronic kidney diseases. The integration of the Chinook team is anticipated to bolster Novartis in expanding its portfolio related to renal conditions and contribute to its ongoing commitment to redefine medicine. Chinook Therapeutics Inc., headquartered in the United States, specializes in developing treatments for rare and severe chronic kidney disorders, including hepatocellular carcinoma (HCC).

Major companies operating in the hepatocellular carcinoma drugs market include AbbVie Inc., Amgen Inc., Bayer AG, Bristol-Myers Squibb Company, Eisai Co.Ltd., Eli Lilly and Company, Johnson & Johnson, Merck & Co. Inc., Novartis AG, Pfizer Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd, Gilead Sciences Inc., Exelixis Inc., Ipsen Pharma Biotech SAS, AstraZeneca plc, BeiGene Ltd., Ono Pharmaceutical Co. Ltd., Roche Holdings AG, Sanofi S.A., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Otsuka Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Hengrui Medicine Co. Ltd., CSPC Pharmaceutical Group Limited, Hutchison China MediTech Limited, Jiangsu Hengrui Medicine Co. Ltd.

North America was the largest region in the hepatocellular carcinoma drug market in 2024. The regions covered in the hepatocellular carcinoma drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hepatocellular carcinoma drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Hepatocellular carcinoma drugs are medications designed for the treatment of primary liver cancer originating from hepatocytes, the primary type of liver cells. Hepatocellular carcinoma often develops in the context of chronic liver diseases, including chronic hepatitis B or C infection, alcoholic liver disease, non-alcoholic fatty liver disease (NAFLD), or liver cirrhosis.

The main types of hepatocellular carcinoma drugs include brachytherapy and chemotherapy. Brachytherapy is a form of radiation therapy employed in cancer treatment, involving the precise placement of radioactive sources directly into or near the tumor site. Radioactive sources used in brachytherapy for hepatocellular carcinoma include iodine-125 and iridium-192. The various drug classes of hepatocellular carcinoma drugs encompass PD-1/PD-L1 inhibitors and tyrosine kinase inhibitors, utilized in settings such as hospitals, clinics, cancer rehabilitation centers, and ambulatory surgical centers.

The hepatocellular carcinoma drugs market research report is one of a series of new reports that provides hepatocellular carcinoma drugs market statistics, including hepatocellular carcinoma drugs industry global market size, regional shares, competitors with a hepatocellular carcinoma drugs market share, detailed hepatocellular carcinoma drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the hepatocellular carcinoma drugs industry. This hepatocellular carcinoma drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hepatocellular carcinoma drug market consists of revenues earned by entities by providing surgery, radiofrequency ablation, and radiation therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The hepatocellular carcinoma drug market also includes sales of cabozantinib, ramucirumab and pembrolizumab drugs used for the treatment of hepatocellular carcinoma drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.